BRPI0409936A - uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico - Google Patents

uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico

Info

Publication number
BRPI0409936A
BRPI0409936A BRPI0409936-2A BRPI0409936A BRPI0409936A BR PI0409936 A BRPI0409936 A BR PI0409936A BR PI0409936 A BRPI0409936 A BR PI0409936A BR PI0409936 A BRPI0409936 A BR PI0409936A
Authority
BR
Brazil
Prior art keywords
partially filled
filled container
medical kit
wall portion
coated glass
Prior art date
Application number
BRPI0409936-2A
Other languages
English (en)
Inventor
Michael Bech Jensen
Birthe Lykkegaard Hansen
Troels Kornfelt
Kirsten Kramer Jakobsen
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34973305&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0409936(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/DK2004/000181 external-priority patent/WO2004082708A2/en
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BRPI0409936A publication Critical patent/BRPI0409936A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F110/00—Homopolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D1/00—Rigid or semi-rigid containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material or by deep-drawing operations performed on sheet material
    • B65D1/02—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Ceramic Engineering (AREA)
  • Mechanical Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Details Of Rigid Or Semi-Rigid Containers (AREA)

Abstract

"USO DE UM MATERIAL, RECIPIENTE PELO MENOS PARCIALMENTE CHEIO, E, KIT MéDICO". Um material escolhido do grupo consistindo de: vidro revestido por sílica, vidro revestido por silicone, polímeros de olefinas não cíclicas, polímeros de ciclo-olefinas e copolímeros de ciclo olefina/olefina linear; é vantajoso como um material de parede interna, em um recipiente que é composto de (i) uma porção de parede e (ii) uma ou mais porções de fechamento que não constituem parte da porção da parede, e que contêm uma formulação de uma proteína tendo um dormínio amino-terminal de ácido <sym>-carboxiglutâmico (Gla) com 9-12 resíduos Gla.
BRPI0409936-2A 2003-05-23 2004-05-21 uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico BRPI0409936A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200300788 2003-05-23
US47628003P 2003-06-05 2003-06-05
PCT/DK2004/000181 WO2004082708A2 (en) 2003-03-18 2004-03-18 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
PCT/DK2004/000359 WO2004103398A1 (en) 2003-05-23 2004-05-21 Protein stabilization in solution

Publications (1)

Publication Number Publication Date
BRPI0409936A true BRPI0409936A (pt) 2006-04-25

Family

ID=34973305

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409936-2A BRPI0409936A (pt) 2003-05-23 2004-05-21 uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico

Country Status (13)

Country Link
US (1) US8536127B2 (pt)
EP (1) EP1628677B1 (pt)
JP (2) JP5627832B2 (pt)
KR (1) KR20060015574A (pt)
CN (1) CN1780638B (pt)
AT (1) ATE454900T1 (pt)
AU (1) AU2004241698A1 (pt)
BR (1) BRPI0409936A (pt)
CA (1) CA2525224A1 (pt)
DE (1) DE602004025100D1 (pt)
MX (1) MXPA05012476A (pt)
RU (1) RU2364609C2 (pt)
WO (1) WO2004103398A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
BRPI0409936A (pt) * 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
WO2005016365A2 (en) * 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
ES2676644T3 (es) * 2003-12-19 2018-07-23 Novo Nordisk Health Care Ag Composiciones estabilizadas de polipéptidos de factor VII
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
WO2008135380A1 (en) * 2007-05-02 2008-11-13 F. Hoffmann-La Roche Ag Method for stabilizing a protein
WO2008135500A1 (en) * 2007-05-02 2008-11-13 Novo Nordisk Health Care Ag High concentration factor vii polypeptide formulations comprising an aromatic preservative and an antioxidant
CN106443002A (zh) * 2007-10-22 2017-02-22 贝克顿·迪金森公司 评价在含有机基聚硅氧烷的悬浮液中蛋白质聚集的方法
NZ622583A (en) * 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
SG10201402265YA (en) * 2008-02-07 2014-08-28 Amgen Inc Stabilized protein compositions
AU2009248885B2 (en) * 2008-05-23 2015-02-05 Hospira, Inc. Packaged iron sucrose products
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US9993597B2 (en) * 2012-05-29 2018-06-12 Becton Dickinson France Lubricant coating and medical injection device comprising such a coating
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
ES2797298T3 (es) 2016-02-10 2020-12-01 Becton Dickinson France Procedimiento para evaluar la estabilidad de una formulación a base de proteína
JPWO2018181531A1 (ja) 2017-03-29 2020-02-06 テルモ株式会社 プレフィルドシリンジ包装体
EP3760220B1 (en) 2018-02-28 2025-02-19 Seikagaku Corporation A package comprising lyophilized chondroitinase abc and method for manufacturing the same
CN114980851A (zh) * 2020-01-28 2022-08-30 日本瑞翁株式会社 预填充药剂包装和预填充药剂包装的制造方法
EP4696321A1 (en) * 2023-04-14 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing protein-containing pharmaceutical preparation

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577070A (en) * 1897-02-16 Machines
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4956386A (en) 1980-04-25 1990-09-11 Gist-Brocades N.V. Pharmaceutical compositions and process for their preparation
US4404132A (en) 1980-05-27 1983-09-13 Cutter Laboratories, Inc. Blood coagulation promoting product
CA1182748A (en) 1980-11-21 1985-02-19 Gerard Marx Method for synthesizing procoagulant factor viii activity
US4495278A (en) 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4382083A (en) 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
EP0225160B1 (en) 1985-11-26 1991-08-21 Novo Nordisk A/S Compositions and methods for the treatment of bleeding disorders
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
EP0272304B1 (en) 1986-06-24 1994-01-26 Novo Nordisk A/S A process for producing a coagulation active complex of factor viii fragments
ES2045167T5 (es) 1987-10-23 1996-07-01 Centre Regional De Transfusion Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
JP2824430B2 (ja) 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
DE3939346A1 (de) 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
CA2074839C (en) 1990-01-29 2000-11-14 Kathleen L. Berkner Modified factor vii anticoagulant proteins
JP3459416B2 (ja) 1991-02-28 2003-10-20 ザイモジェネティクス，インコーポレイティド 修飾されたファクター▲ｖｉｉ▼
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5817788A (en) 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
FR2684999A1 (fr) 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
JP3155797B2 (ja) 1991-12-26 2001-04-16 株式会社日立製作所 過電圧自己保護型半導体装置、及び、それを使用した半導体回路
DE69333928T2 (de) 1992-04-30 2006-08-17 Probitas Pharma Inc., Los Angeles Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
ES2152953T3 (es) 1992-08-27 2001-02-16 Sanquin Bloedvoorziening Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina.
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
PT699075E (pt) 1993-05-21 2002-05-31 Novo Nordisk As Factor vii modificado para inibicao de restenose vascular e de deposicao de plaquetas
WO1995003332A1 (en) 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
US6277828B1 (en) 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US5576291A (en) 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
DE4435520A1 (de) 1994-10-04 1996-04-11 Immuno Ag Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
US5649959A (en) 1995-02-10 1997-07-22 Sherwood Medical Company Assembly for sealing a puncture in a vessel
DE19531637A1 (de) 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
SE9503679D0 (sv) 1995-10-20 1995-10-20 Pharmacia Ab Antioxidants
US5993795A (en) 1995-11-09 1999-11-30 Takemoto Yushi Kabushiki Kaisha Protein composition derived from sesame seed and use thereof
US6320029B1 (en) 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5925738A (en) 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5830852A (en) 1995-12-19 1998-11-03 Cobra Therapeutics, Ltd. Compositions for insulin-receptor mediated nucleic acid delivery
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
DE19903693A1 (de) 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US5910138A (en) * 1996-05-13 1999-06-08 B. Braun Medical, Inc. Flexible medical container with selectively enlargeable compartments and method for making same
AT403989B (de) * 1996-09-16 1998-07-27 Immuno Ag Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
KR101042660B1 (ko) 1996-12-24 2011-06-20 바이오겐 아이덱 엠에이 인코포레이티드 안정한 액체 인터페론 제제
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
DE19730023A1 (de) 1997-07-11 1999-01-14 Bayer Ag Hochreine Ciprofloxacin-Infusion
US6461610B1 (en) 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
JPH11335295A (ja) * 1998-05-22 1999-12-07 Towa Pharmaceutical Co Ltd カルシウム調節ポリペプチドホルモンの安定な非経口投与用水溶液製剤
DE19853033A1 (de) 1998-11-18 2000-05-25 Centeon Pharma Gmbh Stabilisierte Proteinzubereitung für einen Gewebekleber
PT2193809E (pt) 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
JP4674021B2 (ja) 1999-07-13 2011-04-20 ビオヴィトルム・アクチボラゲット（プブリクト） 安定第ｖｉｉｉ因子組成物
DE19937218A1 (de) 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
GB9920772D0 (en) * 1999-09-03 1999-11-03 Nycomed Amersham Plc Improved container composition for radiopharmaceutical agents
GB9920758D0 (en) * 1999-09-03 1999-11-03 Nycomed Amersham Plc Improved container composition for diagnostic agents
ATE389414T1 (de) * 1999-09-08 2008-04-15 Chugai Pharmaceutical Co Ltd Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
US6750053B1 (en) * 1999-11-15 2004-06-15 I-Stat Corporation Apparatus and method for assaying coagulation in fluid samples
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
AU9165201A (en) 2000-10-02 2002-04-15 Novo Nordisk As Factor vii glycoforms
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
DE50114021D1 (de) 2001-01-08 2008-07-24 Csl Behring Gmbh Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
EP1232735A3 (en) 2001-02-20 2004-03-03 SCA Hygiene Products AB Diaper cover and method for manufacturing a diaper cover
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
WO2003039585A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
US7078479B2 (en) 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US7125846B2 (en) 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
US20030119743A1 (en) 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
KR20040065278A (ko) 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
JP2005530682A (ja) 2001-12-21 2005-10-13 ノボ　ノルディスク　アクティーゼルスカブ 修飾第ｖｉｉ因子ポリペプチドの液体組成物
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
US20040009918A1 (en) 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
AT501088A2 (de) 2002-12-18 2006-06-15 Bio Prod & Bio Eng Ag Stabile therapeutische proteine
CA2518327A1 (en) 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
BRPI0409936A (pt) * 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico

Also Published As

Publication number Publication date
US8536127B2 (en) 2013-09-17
ATE454900T1 (de) 2010-01-15
KR20060015574A (ko) 2006-02-17
CN1780638A (zh) 2006-05-31
CA2525224A1 (en) 2004-12-02
JP2007502310A (ja) 2007-02-08
US20060160720A1 (en) 2006-07-20
JP5627832B2 (ja) 2014-11-19
RU2364609C2 (ru) 2009-08-20
JP2012229230A (ja) 2012-11-22
EP1628677B1 (en) 2010-01-13
CN1780638B (zh) 2010-04-14
DE602004025100D1 (de) 2010-03-04
RU2005140282A (ru) 2006-07-27
WO2004103398A1 (en) 2004-12-02
AU2004241698A1 (en) 2004-12-02
MXPA05012476A (es) 2006-02-22
EP1628677A1 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
BRPI0409936A (pt) uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
MXPA03008794A (es) Mejoras en o relacionadas con dispositivos refrescantes de aire.
BRPI0607988A2 (pt) composto, composição farmacêutica, e método para induzir apoptose em uma célula
CA2295247A1 (en) Compositions containing thrombin and microfibrillar collagen
EP1315513A4 (en) CHEMICAL LIGATION &#34;PSEUDO&#34; -NATIVE
IL185142A0 (en) Lentiviral packaging constructs
DK0713529T3 (da) Vækst-/differentieringsfaktor af TGF-beta-familien
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
ES2122520T3 (es) Composicion de limpieza con dos partes que comprende al menos un compuesto de peroxido.
BR9407419A (pt) Implante de tecido mole aperfeiçoado
EP2298287A3 (en) Stabilised compositions of factor VII polypeptides
DE69007662D1 (de) Verpackung zur Aufnahme und Mischung von zwei Komponenten.
BRPI0406652A (pt) Dispositivo refrescante de ar
AU7861201A (en) Process of injection moulding a syringe from polythylene wax containing polypropylene, syringe obtained thereby and particulate composition therefor
AR033788A1 (es) Envase primario, uso de un tapon o embolo de caucho que contiene caucho de bromobutilo para sellar el envase primario y procedimiento para la manufactura del envase primario
DE60239409D1 (de) Mehrkammerreagenzbehälter mit mittel zur verhinderung von dessen wiederverwendung
DOP2001000279A (es) Uso de polimerizados como auxiliares de filtracion y/o estabilizantes.
WO2002032940A3 (en) Osteopontin-coated surfaces and methods of use
ATE206075T1 (de) Isolierscheiben mit wax enthaltende thermoplastischen adsorptionszusammensetzungen
WO2004065410A3 (en) Mntf peptides and compositions and methods of use
ATE298784T1 (de) Wasserlösliche verpackung enthaltend ein mehrphasiges flüssiges waschmittel
WO2002022106A3 (en) Stable ophthalmic preparation
ATE342205T1 (de) Flaschenträger
BR0015640A (pt) Recipiente para produto alimentìcio com espaço contendo gás inerte
EA199801032A1 (ru) Белки zona pellucida для контрацепции

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.